Prevalence of Hepatitis C Virus and its genotypes among a cohort of drug users in Kenya by Muasya, T et al.
318	 E a s t 	 a f r i c a n 	 M E d i c a l 	 J o u r n a l 	 July 2008
Prevalence of hePatitis c virus and its genotyPes among a cohort of 




Background: Prevalence of hepatitis c virus and that of its main genotypes varies between the 
worlds geographic regions. the risk factors for infection with hcv include blood transfusion, 
tattoing and injecting drug use.
Objectives: to examine the prevalence of hcv and determine its main genotypes among a cohort 
of drug users in Kenya.
Design: a laboratory based study.
Setting: hepatitis research laboratory in the centre for virus research at the Kenya medical 
research institute, nairobi.
Subjects: three hundred and fourteen male and 19 female intravenous and non-intravenous drug 
users aged between 15-55 years.
Results: seventy four (22.2%) out of 333 samples tested positive for anti-hcv. sixty nine out of 
the 74 serum samples were assayed for hcv rna and 38 (55.5%) were positive. the rna positive 
samples were further subjected to sequencing and 19 (73%) of the samples were classified as 
genotype la, while seven (27%) samples were classified as genotype 4. Genotypes 2, 3, 5 and 6 were 
not identified in this study.
Conclusions: these results demonstrate a high hcv infection prevalence among this cohort of 
drug users (22.2 %) as compared to that of the general population, which is estimated to be 0.2-
0.9%. The study also confirms the presence of at least two major genotypes among Kenyan drug 
users (genotypes 1 and 4).
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amino	acids.	there	 is	 a	non-coding	 region	 (ncr)	
of	324-341	nucleotides	at	 the	5’	end	and	a	3’	ncr	





i.e.	 cirrhosis	 and	 primary	 liver	 cancer	 as	 well	 as	

















with	 high	 rates	 of	 infection	 seen	 in	 intravenous	
drug	 abusers,	 haemophiliacs	 and	 recipients	 of	
unscreened	 blood	 transfusions.	 the	 possibility	 of	
sexual	 transmission	 cannot	 be	 eliminated,	 but	 if	
it	 occurs,	 the	 risk	 seems	 to	 be	 very	 low.	 vertical	
transmission	of	Hcv	 in utero and	perinatally	 has	
also	been	 reported,	but	again,	 appears	 to	be	 rare.	














KEMri-Jica	 jointly	 assisted	 in	 the	 laboratory	
assay	part	of	the	project.	the	subjects	from	a	wide	
spectrum	 of	 age	 and	 social	 background	 were	








in	 the	 previous	 six	 months)	 and	 non-injectors	
(subjects	whose	mode	of	drug	consumption	is	other	
than	injection)	(table	1).	subject	participation	was	
not	 limited	 to	 a	 particular	 drug.	 after	 informed	
consent	was	obtained,	the	subjects	completed	a	multi	
question	 survey	 questionnaire	 which	 focused	 on	
demographic	information	and	topic	areas	associated	
with	 hepatitis	 c	 transmission	 (intravenous	 drug	
use,	sexual	history,	cultural	practices,	used	needle-
sharing	 behaviours,	 medical	 history).	 the	 333	
subjects	 who	 gave	 informed	 consent	 were	 bled	
at	 various	 locations	 and	 the	 serum	 obtained	 was	
tested	for	anti-Hcv,	HBsag	and	anti-Hiv	by	Murex,	
KEMri	Hepcell	and	vironostika	respectivelly.	for	
Hcv,	 Murex	 anti-Hcv	 version	 4.0	 Eia	 (Murex	
Biotech	sa	ltd,	Kyalami,	south	africa)	was	used.	
The reactive anti-HCV samples were then confirmed 
using	a	third	generation	recombinant	immuno	blot	
assay	 (riBa)	 for	 HBsag,	 latex	 Biotech	 particle	
agglutination	 kit	 (Biotech	 laboratories)	 was	 used	




confirmation done using enzygnost.
HCV RNA determination: sixty	nine	out	of	the	seventy	
four	anti-Hcv	positive	samples	were	determined	
for	 Hcv-rna	 due	 to	 volume	 limitations.	 the	
samples	 were	 stored	 at	 –20ºc	 until	 assay	 time.	
the	purity	of	the	template	rna	is	important	since	
non	nucleic	acid	components	of	serum	or	plasma	
can	 inhibit/contaminate	 the	 cdna	Pcr	reaction.	
complementary	 dna	 was	 synthesised	 with	 a	
reverse	 transcriptase,	 random	 primer,	 5x	 buffer,	
r-nase	inhibitor	and	dntPs	which	were	incubated	
320	 E a s t 	 a f r i c a n 	 M E d i c a l 	 J o u r n a l 	 July 2008
for 90 mins at 37ºC. 45ul of the cDNA amplification 










a	 10ul	 aliquot	 of	 the	 Pcr	 product	 was	 then	
subjected	to	2%	agarose	gel	electrophoresis.	the	gels	
were	 stained	 with	 ethidium	 bromide	 and	 results	
analysed	and	examined	for	the	presence	of	bands	
of the size expected i.e. 215 base pairs.
Sequencing and phylogenetic analysis: complementary	
dna	 was	 synthesised	 and	 the	 cdna	 mixture	
subjected	 to	 Pcr	 with	 primers	 located	 on	 the	




pairs.	 sequencing	 reactions	were	 performed	with	
aBi	 PrisM	 Big	 dye	 terminator	 cycle	 sequencing	
ready	 reaction	 kit,	 and	 the	 the	 aBi	 PrisM	 3100	
genetic analyzer (Applied Biosystems) according 
to	 the	 manufacturers	 protocol.	 the	 nucleotide	
sequences	of	the	determined	Kenyan	Hcv	strains	
(335	 nucleotides)	 were	 aligned	 using	 clustaw	 W.	



























Age groups in relation to status
age	group	 current	users	 Ex-users
(years)	 no.	 (%)	 no.	 (%)
11-20	(n	=	26)	 11	 42.3	 4	 15.3
21-30	(n	=	186)	 52	 27.9	 31	 16.6
31-40	(n	=	99)	 38	 38.3	 13	 13.1
41-50	(n	=	19)	 0	 0	 2	 10.5
51-60	(n	=	3)	 3	 100	 0	 0
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out	 of	 the	 333	 samples,	 74,	 15	 and	 74	 were	
positive	 for	 anti-Hcv,	 HBsag	 and	 anti-Hiv	
respectively.	 out	 of	 the	 74	 anti-Hcv	 reactive	
samples, five could not be analysed by PCR due to 
volume	limitations.	a	proportion	of	38	of	69	(55.5%)	




Infection among different age groups
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among	 the	 drug	 injectors,	 57	 (60.6%)	 of	 the	
current	 injectors	 were	 positive	 for	 anti-Hcv	 as	
compared	to	the	ex-injectors	who	were	10	(19.6%).	
This difference is significant p<0.0001. Infection with 
HBv	was	high	with	six	(6.4%)	among	the	current	
injectors	 while	 that	 of	 the	 ex-injectors	 was	 three	
(5.8%). This was insignificant p>0.9999. About 47 
(50%)	of	the	current	drug	users	tested	positive	for	
anti-HIV as compared to only five (9.8%) of the 
ex-injectors. Here the difference was significant 









eight (42.6%), a significant difference p=0.0352. For 
HBv,	15	(4.8%)	males	tested	positive	and	all	females	
tested negative. This was insignificant p>0.9999. For 
anti-Hiv,	63	(20%)	males	tested	positive	compared	
to 11 (57.9%) females, a significant difference p = 
0.0005	(table	3).





26	 Kenyan	 sequences	 were	 aligned	 with	 37	 Hcv	
reference	strains	from	the	genebank	database.	the	
characterisation	 of	 the	 viral	 genotypes	 indicated	
that	of	the	Hcv	strains,	19	(73%)	were	of	genotype	






K108,	 K193	 and	 K30	 in	 genotype	 4	 ranged	 from	
96.1%-100%.	the	nucleotide	sequences	homologies	
between	 samples	 in	 genotype	 1	 and	 those	 in	
genotype	4	ranged	from	67-70.2%.
figure 2
HCV, HBV and HIV infection rates among different drug user populations. (Current injectors n=94, ex-injectors 
n=51, non-injectors n=188)
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table 3
Infection in relation to gender
gender	 anti-Hcv	+	 P-value	 HBsag	+		 P-value	 anti-Hiv	+	 P-value
	 no.		(%)	 	 no.		(%)	 	 no.		(%)
Males	(n	=	314)	 61			19.4	 p	=	0.0352	 15				4.8	 p	=	0.9999	ns	 63					20	 p	=	0.0005
females	(n	=	19)		 8					42.1	 	 0							0	 	 11				57.9
figure 3
Phylogenetic tree of HCV strains from Kenyan isolates with reference strains. The 26 Kenyan sequences were 
aligned with 37 HCV reference strains from the gene bank data base. The six major lineages of HCV are indicated 





the	 number	 of	 injectors	 were	 18	 and	 5	 while	 the	
non-injectors were one and five for genotypes 1 
and	4	respectively.	among	the	injectors,	the	current	
ones	 were	 17	 and	 4	 as	 compared	 to	 one	 and	 one	
for	ex-injectors	for	genotypes	1	and	4	respectively.	
There is no statistical significant difference between 
genotype	 and	 gender	 p	 =	 0.4738,	 genotype	 and	
drug	consumption	mode	p	=	0.1669,	genotype	and	
injection	status	p	=	0.1433	(table	4).
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discussion
from	this	study	we	observed	that	there	were	more	
non-intravenous	 drug	users	 than	 the	 intravenous	








than	 the	 ex-users.	 apart	 from	 the	 spread	 of	 the	











drugs and cigarettes. There is also a lot of influence 
and	 idleness	 because	 it	 is	 at	 this	 age	 when	 most	
people	have	just	completed	college	and	are	frustrated	
by	 lack	 of	 securing	 jobs	 in	 major	 urban	 centres.	
from	this	study	we	also	observe	that	infection	with	
Hcv	was	high	among	the	21-40	year	age	groups.	

















viraemia	 with	 Hcv	was	 detected	 in	 majority	
of	 the	 intravenous	drug	users.	Probably	 it	would	
have	been	detected	in	more	samples	were	they	to	
be	assayed	immediately	after	collection,	the	reason	
being	 denaturation	 of	 the	 nucleic	 acids	 during	
storage	 and	 transportation	 of	 the	 samples	 from	
one	 laboratory	 to	 another	 for	 different	 analytical	
procedures.	determination	of	absence	of	viraemia	
in	this	study	was	based	on	a	single	negative	Pcr	
test,	which	 cannot	 rule	out	viraemia	at	 an	earlier	
stage	of	infection.
transmission	 between	 different	 sexes	 is	 often	
assumed	 to	 be	 sexual.	 However	 other	 routes	 of	
transmission	cannot	be	ruled	out.	Males	comprised	
the	 majority	 of	 the	 drug	 users.	 this	 is	 evident	 in	
many	 societies	 whereby	 the	 male	 population	 is	
usually	dominant	when	it	comes	to	substance	abuse,	




grouped	 into	 six	 main	 genotypes, one	 to	 three	
accounting	 for	most	 infections	 in	 Japan, u.s.a	and	













Comparison between genotypes 1 and 4
status	 genotype	1a	(n	=	19)	 genotype	4	(n	=	7)	 P-value
age	(mean)	 26	 31
gender	(M/f)	 18/1	 6/1	 p	=	0.4738
injector/non-injector	 18/1	 5/2	 p	=	0.1669
current/ex-user	 17/1	 4/1	 p	=	0.1433







another	 study	 carried	 out	 in	 Egypt	 reported	
similar findings whereby Egyptian HCV epidemic 
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